Agilent Technologies and Callida Genomics Sign Licensing Agreement for DNA Microarray Patents
PALO ALTO, Calif. & SUNNYVALE, Calif.--(BUSINESS WIRE)--May 20, 2002--Agilent Technologies Inc. (NYSE:A - News) and Callida Genomics Inc., a majority-owned subsidiary of Hyseq Pharmaceuticals Inc. (Nasdaq:HYSQ - News), today announced a non-exclusive licensing agreement that grants Callida both up-front fees and potential running royalties, and gives Agilent access to Callida's early microarray patent portfolio for commercial use in the field of non-universal DNA microarrays.
"This license enhances our extensive microarray patent portfolio and furthers our ability to bring new DNA microarray solutions to the life sciences community," said Barney Saunders, vice president and general manager of Agilent's Bioresearch Solutions business. "This agreement secures access to an important set of patents derived from Dr. Radoje Drmanac, currently CSO at Callida, who conducted pioneering work in the early development of microarrays."
"We are pleased that Agilent is able to utilize our DNA microarray patents," said George Rathman, interim president, chairman and CEO of Callida Genomics. "This agreement fits nicely with our licensing strategy for non-universal probes, further validating the strength of our patent portfolio and providing us with future royalty revenue opportunities."
About Callida Genomics Inc.
Callida Genomics, Inc., a majority owned subsidiary of Hyseq Pharmaceuticals, Inc. (Nasdaq:HYSQ - News), is focused on the development and commercialization of advanced DNA sequencing and analysis tools based upon its sequencing-by-hybridization technology. The company's core business is based on universal DNA probe products that are applicable to any gene or genomic application, including DNA sequencing, genotyping and gene expression. Callida also offers licenses to other established companies that utilize probes in non-universal DNA analysis products. Information about Hyseq Pharmaceuticals and Callida Genomics is available at www.hyseq.com or by phoning 408/524-8100.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A - News) is a global technology leader in communications, electronics and life sciences. The company's 39,000 employees serve customers in more than 120 countries. Agilent had net revenue of $8.4 billion in fiscal year 2001. Information about Agilent is available on the Web at www.agilent.com.
Callida's Safe Harbor
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding the business of Hyseq Pharmaceuticals, Inc. and its subsidiary, Callida Genomics, Inc. which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.
Agilent's Safe Harbor
This news release contains forward-looking statements (including, without limitation, statements relating to the intended future production of DNA microarrays) that involve risks and uncertainties that could cause results of Agilent Technologies to differ materially from management's current expectations. These risks are detailed in reports filed with the Securities and Exchange Commission, including Agilent's Annual Report on Form 10-K/A filed Feb. 1, 2002, and Form 10-Q filed March 6, 2002.
--------------------------------------------------------------------------------
Contact:
Agilent Technologies Inc.
Doug Forsyth, 650/485-5603
doug_forsyth@agilent.com
or
Callida Genomics
Nicole Estrin, 408/746-4572
nestrin@hyseq.com |
